Oxford, UK – 16 June 2025: OXB has been ranked 34th out of 300 organisations in Fortune’s list of Europe’s most innovative companies, a recognition that underscores the company’s leadership in cell and gene therapy innovation. The list, compiled based on evaluations by industry experts and employees, highlights businesses delivering meaningful innovation across sectors including life sciences, technology and manufacturing.
A leading cell and gene therapy contract development and manufacturing organisation (CDMO) with 30 years of viral vector expertise, OXB currently supports 48 client programmes across the UK, France and US. It is one of just 22 UK-based and one of only four healthcare organisations to earn a place on the prestigious list.
OXB’s innovation strategy is committed to helping clients overcome the complex landscape of developing and manufacturing cell and gene therapies. The company continues to advance its proprietary inAAVate™ and LentiVector™ platforms, for AAV and lentiviral vectors respectively, delivering greater scalability, performance and process efficiency.
“Being named one of Europe’s most innovative companies is a powerful affirmation of our mission,” said Dr. Frank Mathias, Chief Executive Officer, OXB. “Innovation at OXB is purpose-driven, focused on empowering our clients to bring transformative cell and gene therapies to patients. This recognition reflects the dedication of our teams across the globe who consistently push the boundaries of what’s possible in advanced therapy development and manufacturing.”
Read more on Fortune’s website.
